Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

INmune Bio Inc. - Common stock (NQ:INMB)

2.360 +0.270 (+12.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about INmune Bio Inc. - Common stock

< Previous 1 2 3 4 Next >
Earnings Scheduled For March 28, 2024
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. 
Via Benzinga
A Preview Of INmune Bio's Earnings
Via Benzinga
Why Is Elevai Labs (ELAB) Stock Up Today?
Elevai Labs is soaring on an intriguing licensing agreement with INmune Bio, but the narrative presents a mixed bag for ELAB stock. 
Via InvestorPlace
Earnings Outlook For INmune Bio
Via Benzinga
INmune Bio's Earnings Outlook
Via Benzinga
INmune Bio Earnings Perspective: Return On Capital Employed
Via Benzinga
Earnings Preview: INmune Bio
Via Benzinga
Why Elevai Labs Stock Is Trading Higher
Elevai Labs, Inc. (NASDAQ:ELAB) shares are trading higher Tuesday after the company announced it signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers as we check out all of the most recent news for Tuesday morning! 
Via InvestorPlace
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Biotech companies are edging closer to finding the answers behind Alzheimer's disease. 
Via Investor's Business Daily
INmune Bio – Helping Your Own Cells Fight Cancer And Reverse Alzheimer's Disease
David Moss, CEO of INmune Bio (NASDAQ: INMB) was recently a guest on Benzinga’s All-Access. 
Via Benzinga
INmune Bio's INKmune Shows Positive Efficacy In Multiple Cancer Cell Lines
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2023
Via Benzinga
The 7 Best Biotech Stocks for Personalized Medicine Investors
Personalized Medicine Stocks Promise to Make Healthcare More Individualized with therapeutics based on individual genetics. 
Via InvestorPlace
Dow Jumps 250 Points; US Jobless Claims Increase Last Week
U.S. stocks traded higher this morning, with the Dow Jones jumping around 250 points on Thursday. The Dow traded up 0.75% to 34,204.99 while the NASDAQ rose 1.15% to 12,047.28. The S&P 500 also rose,... 
Via Benzinga
Nasdaq Tumbles 150 Points; Crude Oil Up 1.5%
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping over 150 points on Wednesday. The Dow traded down 0.27% to 34,063.42 while the NASDAQ fell 1.33% to 11,952.51. The... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Recap: INmune Bio Q2 Earnings
INmune Bio (NASDAQ:INMB) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings INmune Bio beat estimated... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
71 Biggest Movers From Yesterday
Gainers CynergisTek, Inc. (NYSE: CTEK) shares surged 100% to close at $1.18 on Tuesday after the company entered into a definitive agreement to be acquired by Clearwater Compliance for roughly $17.7... 
Via Benzinga
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
50 Stocks Moving In Tuesday's Mid-Day Session
Gainers CynergisTek, Inc. (NYSE: CTEK) jumped 100% to $1.18 after the company entered into a definitive agreement to be acquired by Clearwater Compliance for roughly $17.7 million. 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022
Upgrades 
Via Benzinga
A Preview Of INmune Bio's Earnings
INmune Bio (NASDAQ:INMB) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that INmune Bio will... 
Via Benzinga
34 Stocks Moving In Monday's Mid-Day Session
Gainers Nkarta, Inc. (NASDAQ: NKTX) shares jumped 108.6% to $16.21 after the company announced Phase 1 data from independent dose finding studies of its two lead chimeric antigen... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Nkarta, Inc. (NASDAQ: NKTX) shares climbed 140.9% to close at $18.72 on Monday after the company announced Phase 1 data from independent dose finding studies of its two... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
63 Biggest Movers From Yesterday
Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its CFO Bruce Colwill will retire. Global Internet... 
Via Benzinga
34 Stocks Moving In Thursday's Mid-Day Session
Gainers JX Luxventure Limited (NASDAQ: LLL) shares jumped 37.7% to $4.64. Emclaire Financial Corp (NASDAQ: EMCF) shares climbed 32.8% to $38.35 after the company and... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.